

65 College of Pathologists' Cytology classification [10]. He
 66 underwent an extended left hemi thyroidectomy 3 weeks
 67 following his initial presentation. After resection, a size
 68 7 drain was placed, and the incision was closed in layers
 69 with 3-0 vicryl and 4-0 monocryl sutures.

70 Histology confirmed a pT2 N0 PTC. Multidisciplinary
 71 Team (MDT) discussion recommended completion of thy-
 72 roidectomy and radioiodine. However, following patient
 73 discussion, he declined further surgical intervention, opt-
 74 ing for conservative management with serial ultrasound
 75 (US) monitoring. Subsequent US in August 2020 con-
 76 firmed no evidence of recurrence.

77 During routine follow-up in September 2022, the
 78 patient reported a 3-month history of a new small, painless
 79 nodule at the left end of his scar. US found two hypoechoic
 80 subcutaneous nodules (4×4 and 3×3 mm) within the
 81 scar, confirmed as metastatic subcutaneous PTC follow-
 82 ing FNAC (Figure 1A). Staging computed tomography
 83 (CT) in December 2022 identified a 6 mm subcutaneous
 84 mass, suggestive of metastasis (Figure 1B). The patient
 85 underwent a complete thyroidectomy with scar excision
 86 in February 2023. No drain was used, and the wound
 87 was closed in layers with dissolvable 4-0 Vicryl and 4-0
 88 Monocryl sutures. Histology confirmed a subcutaneous
 89 PTC (pT2 R0 M1). Following an MDT discussion, the
 90 patient received radioactive iodine in June 2023.

At routine follow-up in February 2024, US showed an
 $8 \times 10 \times 13$ mm hypoechoic nodule with microcalcifica-
 tions and some internal vascularity arising from the left
 strap muscle near the left thyroid bed. CT neck and thorax
 further confirmed the presentation and excluded additional
 foci of disease. Following MDT discussion, the patient
 received additional radioactive iodine in June 2024.

Case 2 Presentation

A 75-year-old female initially presented to an inner-city
 district general hospital in 2018 with a large, right-sided
 symptomatic goitre. She subsequently underwent routine
 US in March 2018 with FNAC, which identified a $78 \times$
 33 mm U4 nodule within the right thyroid. FNAC was
 classified as Thy3f, suspicious for a follicular-variant
 PTC. CT confirmed a multinodular goitre causing slight
 tracheal deviation to the right with moderate narrowing of
 the tracheal lumen. Diagnostic right hemithyroidectomy
 confirmed a non-encapsulated follicular variant PTC
 staged as pT3. Following MDT recommendation, the
 patient underwent a complete left hemithyroidectomy and
 received adjuvant therapy with radioactive iodine.

In March 2023, the patient re-presented with a central
 neck mass (Figure 2) and raised thyroglobulin antibodies
 (269.93 IU/ml, reference range <115 IU/ml). Her care
 was transferred to a tertiary centre, and staging CT in
 May 2023 confirmed a 6.5×5 mm lesion within the right




Figure 1. A - US suggestive of an $8 \times 10 \times 13$ mm hypoechoic nodule with microcalcification and internal vascularity. B - Axial CT demonstrating a small subcutaneous nodule just superficial to the anterior border of the left SCM.



Figure 2. Clinical presentation with pre-operative markings.

117 tracheoesophageal groove and an additional 7.5 × 7.5 mm
 118 mass located inferiorly (Figure 3). A further three subcu-
 119 taneous nodules were identified within the sternal notch,
 120 measuring 15, 13, and 10.5 mm in diameter. An additional
 121 11 and 16.5 × 12.5 mm nodules were also reported within
 122 the lower aspect of the right sternocleidomastoid muscle
 123 (SCM). Finally, a small 3.5 mm nodule in the left upper
 124 lobe of the lung was identified, further suggestive of
 125 metastasis. Lung nodules were not biopsied.

126 Following MDT discussion, further surgical interven-
 127 tion was recommended, and the patient underwent cen-
 128 tral neck dissection in June 2023. Multiple subcutaneous
 129 deposits of PTC were discovered within the scar, ranging
 130 from 6 to 18 mm. A further five masses were then removed
 131 from the central neck. The wound was closed in layers
 132 using 3-0 vicryl and 4-0 prolene sutures, and no drain was
 133 required. Finally, following MDT discussion, the patient
 134 underwent radioactive iodine treatment in September
 135 2023, and on follow-up US in October 2024, she was free
 136 of disease.

137 **Case 3 Presentation**

138 A 58-year-old female presented to an inner-city district
 139 general hospital in June 2023 with a rapidly growing left-
 140 sided neck lump. US and CT imaging revealed a 3.5 × 3.7
 141 cm left thyroid nodule with early strap muscle invasion,
 142 confirmed as malignant following FNAC (Thy 5).

143 She underwent total thyroidectomy in August 2023. A
 144 size 7 Surgidyne drain was used, and the incision closed
 145 in layers with 3-0 vicryl and 4-0 monocryl. Histological
 146 analysis confirmed a pT3a PTC, and MDT discussion rec-
 147 ommended adjuvant radioactive iodine ablation.

During routine follow up in January 2024, she was noted
 to have two small superficial subdermal nodules on the left
 side of the scar. Post treatment radioactive iodine imaging
 showed intense uptake within the anterior neck. Both thy-
 roglobulin (12.0 ug/l, reference range <0.1 ug/l) and thy-
 roglobulin antibodies (272 IU/ml, reference range <115 IU/
 ml) were elevated. Additional CT imaging identified dermal
 nodules suggestive of local recurrence and three pulmonary
 nodules suggestive of metastasis (Figure 4). In March 2024,
 she underwent a limited central neck dissection and local
 excision of subcutaneous nodules. No drain was used, and
 the incision was closed in layers using 3-0 vicryl and 4-0
 monocryl. Her levothyroxine dose was increased further
 to 150 mcg daily to maintain thyroid-stimulating hormone
 suppression. Histology confirmed two separate deposits of
 metastatic PTC. The patient underwent further radioactive
 iodine therapy following MDT discussion.

Surveillance CT imaging in September 2024 identified
 progression of lung metastases, a progressive enhanc-
 ing soft tissue mass (2 × 1.5 cm), and two new deposits
 of disease (0.5 and 0.8 cm), one of which was eroding
 the thyroid cartilage. She was offered laryngectomy for
 locoregional control or receptor tyrosine kinase inhibitor
 therapy with Lenvatinib. She opted for systemic therapy,
 which began in November 2024. Follow-up CT imaging
 in January 2025 showed stable disease.

174 **Discussion**

175 Cutaneous metastases from PTC are an exceedingly rare
 176 manifestation. We describe three cases of cutaneous metas-
 177 tasis of PTC, presenting 5, 24, and 60 months following
 178 initial surgery, reflecting similar rates to the literature [5].
 179 Two of these cases were female and one male, with a mean




Figure 3. A - Axial CT demonstrating multiple subcutaneous deposits within the sternal notch. B - Two US images highlighting multiple small subcutaneous metastatic deposits.

180 age of 69.67 years (SD 8.80) at presentation of cutaneous
181 metastasis. This corresponds with other reported cases,
182 which demonstrate a female preponderance (55%) and an
183 average age at presentation of cutaneous disease of 63.13
184 years and a high prevalence of PTC (47%) [5]. Although
185 PTC has an excellent overall prognosis, distant metastases
186 are typically associated with poor outcomes [2,5].

187 All three cases in this series demonstrated cutaneous
188 recurrence within the neck, specifically in or adjacent to
189 previous surgical scars. This contrasts with existing liter-
190 ature, which most commonly identifies cutaneous metas-
191 tases from PTC presenting on the scalp, likely due to its
192 rich lymphovascular network facilitating distant spread
193 [6]. Notably, none of our cases involved a documented




Figure 4. A - Axial CT demonstrating subcutaneous deposit of PTC with invasion of the left anterior strap muscles. B - US suggestive of two metastatic deposits within the dermis.

Table 1. Summary of case characteristics.

| | Age | Time to metastases (post initial resection) | Site of metastases | Management | Outcome |
|--------|-----|---|---------------------------------------|---|--------------------------------------|
| Case 1 | 68 | 24 months | Surgical scar | Completion thyroidectomy, scar excision, and radioactive iodine | Ongoing monitoring (as of June 2024) |
| Case 2 | 75 | 60 months | Surgical scar, sternal notch, and SCM | Central neck dissection and radioactive iodine | Disease-free (as of Oct 2024) |
| Case 3 | 58 | 5 months | Surgical scar | Central neck dissection, radioactive iodine, and systemic therapy | Stable disease (as of Jan 2025) |

195 intraoperative breach of the tumour capsule, raising ques-
 196 tions regarding the pathogenesis of these recurrences.
 197 These findings challenge whether such lesions should
 198 be classified as truly distant metastasis (M1), or rather as
 199 manifestations of locoregional tumour seeding, but this
 200 remains speculative. All three patients underwent revision
 201 surgery with curative intent and exhibited only low-vol-
 202 ume distant disease. If these cutaneous lesions repre-
 203 sented conventional distant metastases, a more extensive
 204 metastatic burden would typically be anticipated. This

discrepancy suggests other factors, including tumour dor-
 205 mancy, local tissue microenvironment, or surgical manip-
 206 ulation, may play a role in localised dermal recurrence.
 207 Importantly, this distinction is not merely academic; each
 208 patient underwent curative surgical revision, yet treatment
 209 approaches would differ significantly had these lesions
 210 been considered true systemic metastases.
 211

212 Diagnosis of cutaneous metastatic PTC lesions is
 213 particularly challenging, not only due to their rare pres-
 214 entation but also because primary skin cancers (such as

apocrine tumours) may demonstrate similar histological features [11]. The mechanism of cutaneous metastases remains unknown. Avram et al proposed tumour cell emboli may become trapped within the rich dermal capillary network [12]. The type of tumour may also influence the risk of skin metastasis. Medullary and anaplastic thyroid cancers are known to carry a greater risk of distant metastasis, although the literature is limited reporting their spread to the skin [5,13,14]. Notably, Lim et al. [15] describe one case of anaplastic thyroid carcinoma with abdominal cutaneous spread.

PTC initially metastasizes through the lymphatic system, resulting in multifocal lesions and regional node metastasis in approximately 50% of cases [2]. Given that PTC is associated with high rates of locoregional metastases, and all three of our patients presented with recurrence associated with a previous surgical scar, it is possible that intraoperative techniques may contribute to pathology. We hypothesize that, for example, a lymph node may have become trapped within the scar during extraction, or the tumour capsule may have been breached intraoperatively. Skin contamination may have occurred whilst removing the specimen through a small incision, or along the drain site. This is particularly exemplified in case 2, where recurrent disease was found within the SCM, near to the site of typical drain insertion.

Interestingly, in the largest systematic review to date, analysis of 136 patients demonstrated that cutaneous metastases as an initial presentation were not uncommon, representing 24.26% of their study population [5]. In these cases, different modes of dissemination of disease to the skin should to be considered as there are likely multiple routes of metastases.

Conclusion and Recommendations

Cutaneous metastases of PTCs are incredibly rare and usually associated with disseminated metastatic disease [6]. They typically present as painless, slow-growing skin nodules found within the head and neck, which may be related to the rich dermal vasculature of the head and neck, or following tumour seeding after FNAC. Excision, further radioactive iodine, and suppression with levothyroxine are recommended. External beam radiation therapy has also been used in palliative instances. Given the poor prognostic association shown in the literature, it is essential to diagnose cutaneous metastasis early. Although, in this case series, the patients showed good locoregional control and stable disease with systemic therapy.

Recommendations for future practice include the prompt evaluation of any skin lesions in patient with a history of thyroid malignancy, alongside thorough examination during routine postoperative follow up. For suspected skin metastasis, evaluation with US, FNAC and CT

imaging should be followed by excisional biopsy in cases of diagnostic uncertainty. Specimens should be reviewed by histopathologists who specialize in thyroid malignancies, given PTC metastasis bear similar histopathological resemblance to primary malignancies like apocrine tumours [11]. Keeping in mind a hypothesis of possible spread through surgical techniques, we careful handling of thyroid specimens remains essential to prevent tumour spillage. Ensuring an adequately sized incision may help reduce the risk of tumour seeding during specimen extraction. Additionally, surgical drains should be positioned away from the tumour bed to minimise the likelihood of cutaneous metastasis. For all revision or completion thyroid surgeries, we routinely excise the surgical scar to enhance cosmetic outcomes, and send this excised scar tissue separately for histopathological diagnosis to rule out potential cutaneous metastasis. This is not routine practice but an institution normal and a suggested recommendation. Although these remain a rare occurrence, it is critical that skin lesions be worked up appropriately and in a timely manner, especially in patients with a history of thyroid malignancy.

What is new?

Cutaneous metastases of papillary thyroid cancer is a rare finding. Although the prognosis of PTC itself is very good, cutaneous presentation is a significant poor prognostic factor with an associated average survival of 13.07 months. The mechanism of action, as well as the best approach to treatment, is still unclear due to limited data. This manuscript provides additional data to add to the pool of only 136 patients currently described in the literature.

List of Abbreviations

| | | |
|------|---------------------------------|-----|
| CT | Computed Tomography | 300 |
| FNAC | Fine-Needle Aspiration Cytology | 301 |
| MDT | Multidisciplinary Team | 302 |
| PTC | Papillary Thyroid Carcinoma | 303 |
| SCM | Sternocleidomastoid | 304 |
| US | Ultrasound | 305 |

Conflict of interest

The authors declare that they have no conflict of interest regarding the publication of this article.

Funding

None.

Consent to participate

For this type of study informed consent is not required.

Consent for publication

For this type of study consent for publication is not required.

Ethical approval

Ethical approval is not required at our institution to publish an anonymous case series.

318 **Availability of data and materials**

319 Not applicable for this article.

320 **Code availability**

321 Not applicable for this article.

322 **Author details**

323 Daniela Bley Sebastiani¹, Theodora Hill², Emma Watts², Jonathan
324 Fussey², Paul Nankivell², Neil Sharma²

325 1. Department of Otolaryngology and Head and Neck Surgery,
326 Heartlands Hospital, Birmingham, UK

327 2. Department of Otolaryngology and Head and Neck Surgery,
328 Queen Elizabeth Hospital, Birmingham, UK

329 **References**

330 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics,
331 2022. *CA Cancer J Clin.* 2022;72(1):7–33. <https://doi.org/10.3322/caac.21708>
332
333 2. Livolsi VA. Papillary thyroid carcinoma: an update. *Mod*
334 *Pathol.* 2011;24(Suppl 2):S1–9. [https://doi.org/10.1038/](https://doi.org/10.1038/modpathol.2010.129)
335 [modpathol.2010.129](https://doi.org/10.1038/modpathol.2010.129)
336 3. Kwon H, Kim H, Park S, Song DE, Kim WG, Kim TY, et al.
337 Solitary skin metastasis of papillary thyroid carcinoma.
338 *Endocrinol Metab (Seoul).* 2014;29(4):579–83. [https://](https://doi.org/10.3803/EnM.2014.29.4.579)
339 doi.org/10.3803/EnM.2014.29.4.579
340 4. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR,
341 Gorman CA, Hay ID. Distant metastases in papillary thyroid
342 carcinoma: 100 cases observed at one institution during
343 5 decades. *J Clin Endocrinol Metab.* 1995;80(7):2041–5.
344 <https://doi.org/10.1210/jcem.80.7.7608252>
345 5. Sciscent BY, Eberly HW, Goyal N, Goldenberg D.
346 Thyroid cancer with cutaneous metastases. *Ear Nose*
347 *Throat J.* 2024;1455613241239533. <https://doi.org/10.1177/01455613241239533>
348
349 6. Dahl PR, Brodland DG, Goellner JR, Hay ID. Thyroid car-
350 cinoma metastatic to the skin: a cutaneous manifes-
351 tation of a widely disseminated malignancy. *J Am Acad*
352 *Dermatol.* 1997;36(4):531–7. [https://doi.org/10.1016/](https://doi.org/10.1016/S0190-9622(97)70239-1)
353 [S0190-9622\(97\)70239-1](https://doi.org/10.1016/S0190-9622(97)70239-1)
354 7. Shon W, Ferguson SB, Comfere NI. Metastatic Hürthle cell
355 carcinoma of the thyroid presenting as ulcerated scrotum

nodules. *Am J Dermatopathol.* 2010;32(4):392–4. <https://doi.org/10.1097/DAD.0b013e3181c1acaf> 356
357
8. Alwaheeb S, Ghazarian D, Boerner SL, Asa SL. Cutaneous 358
manifestations of thyroid cancer: a report of four cases 359
and review of the literature. *J Clin Pathol.* 2004;57(4):435– 360
8. <https://doi.org/10.1136/jcp.2003.012922> 361
9. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard 362
Ba G, et al. Guidelines for the management of thyroid 363
cancer. *Clin Endocrinol (Oxf).* 2014;81(s1 Suppl 1):s1–122. 364
<https://doi.org/10.1111/cen.12515> 365
10. Royal College of Pathologists. Guidance on the report 366
ing of thyroid cytology specimens. London, UK: Royal 367
College of Pathologists; 2024. Available from: [https://](https://www.rcpath.org/static/d40af26c-0e49-4d40-8fce4a-38f2a5c44b/G089-Guidance-on-the-reporting-of-thyroid-cytology-specimensFor-Publication.pdf) 368
[www.rcpath.org/static/d40af26c-0e49-4d40-8fce4a-](https://www.rcpath.org/static/d40af26c-0e49-4d40-8fce4a-38f2a5c44b/G089-Guidance-on-the-reporting-of-thyroid-cytology-specimensFor-Publication.pdf) 369
[38f2a5c44b/G089-Guidance-on-the-reporting-of-](https://www.rcpath.org/static/d40af26c-0e49-4d40-8fce4a-38f2a5c44b/G089-Guidance-on-the-reporting-of-thyroid-cytology-specimensFor-Publication.pdf) 370
[thyroid-cytology-specimensFor-Publication.pdf](https://www.rcpath.org/static/d40af26c-0e49-4d40-8fce4a-38f2a5c44b/G089-Guidance-on-the-reporting-of-thyroid-cytology-specimensFor-Publication.pdf) 371
11. Romanelli P, Mejias A, Isaac G, Sasken H. 372
Cutaneous metastasis from papillary thyroid carci- 373
noma. *Am J Dermatopathol.* 1994;16. <https://doi.org/10.1097/00000372-199402000-00049> 374
12. Avram AM, Gielczyk R, Su L, Vine AK, Sisson JC. Choroidal 375
and skin metastases from papillary thyroid cancer: 376
case and a review of the literature. *J Clin Endocrinol* 377
Metab. 2004;89(11):5303–7. [https://doi.org/10.1210/](https://doi.org/10.1210/jc.2004-0757) 378
[jc.2004-0757](https://doi.org/10.1210/jc.2004-0757) 379
13. Randle RW, Balentine CJ, Levenson GE, Havlena JA, Sippel 381
RS, Schneider DF, et al. Trends in the presentation, treat- 382
ment, and survival of patients with medullary thyroid 383
cancer over the past 30 years. *Surgery.* 2017;161(1):137– 384
46. <https://doi.org/10.1016/j.surg.2016.04.053> 385
14. Lee JS, Lee JS, Yun HJ, Chang H, Kim SM, Lee YS, et al. 386
Prognosis of anaplastic thyroid cancer with distant 387
metastasis. *Cancers (Basel).* 2022;14(23):5784. <https://doi.org/10.3390/cancers14235784> 388
15. Lim KH, Lee KW, Kim JH, Park SY, Choi SH, Lee JS. Anaplastic 390
thyroid carcinoma initially presented with abdominal 391
cutaneous mass and hyperthyroidism. *Korean J Intern* 392
Med (Korean Assoc Intern Med). 2010;25(4):450–3. 393
<https://doi.org/10.3904/kjim.2010.25.4.450> 394

Summary of the case

| | Case 1 | Case 2 | Case 3 |
|------------------------|---|--|---|
| Patients (gender, age) | Male, 68 | Female, 75 | Female, 58 |
| Final diagnosis | Cutaneous metastases of papillary thyroid cancer | | |
| Symptoms | Nodule on scar | Central neck mass | Subdermal nodules |
| Intervention | Completion thyroidectomy, scar excision, and radioactive iodine | Central neck dissection and radioactive iodine | Central neck dissection, radioactive iodine, and systemic therapy |
| Outcome | Ongoing monitoring (as of June 2024) | Disease-free (as of Oct 2024) | Stable disease (as of Jan 2025) |
| Specialty | Head and Neck / Otolaryngology | | |